Organ Transplantation: Process, Types, Risks & Long-Term Care

Organ transplantation replaces a failing organ with a healthy one from a deceased or living donor. It is a life-saving but complex therapy requiring lifelong immunosuppression and multidisciplinary care.

Transplant Types & Indications

Organ	Common Indications	Living Donor Option
Kidney	ESRD (diabetes, HTN, GN, PKD)	Yes (preferred)
Liver	Cirrhosis (HCV, alcohol, NASH, PBC, PSC), acute liver failure, HCC	Yes (partial lobe)
Heart	End-stage cardiomyopathy (ischemic, dilated, restrictive)	No
Lung	COPD, IPF, CF, PAH, bronchiectasis	No (lobar from 2 donors — rare)
Pancreas	Type 1 DM with renal failure (simultaneous pancreas-kidney)	No
Intestine	Short bowel syndrome, TPN failure	Rare
Hematopoietic (Bone Marrow/Stem Cell)	Leukemia, lymphoma, myeloma, aplastic anemia, hemoglobinopathies, immunodeficiency	Yes (matched related/unrelated)

Pre-Transplant Evaluation

• Medical: Organ-specific function, comorbidities, cancer screening, infection workup (TB, viral serologies), cardiac/pulmonary testing
• Psychosocial: Support system, adherence history, mental health, substance use, financial/insurance clearance
• Immunologic: ABO, HLA typing, PRA (panel reactive antibody), crossmatch

Waitlist & Allocation

• UNOS/OPTN policies: MELD-Na (liver), LAS (lung), KDPI/KDRI (kidney), heart/lung status tiers
• Wait times vary by organ, blood type, geography, sensitization (cPRA)
• Living donor bypasses waitlist; scheduled electively

Perioperative & Early Post-Transplant

• Surgery: 4–12+ hours; ICU stay days to weeks
• Immunosuppression induction: Basiliximab (IL-2R antagonist) or thymoglobulin (T-cell depletion)
• Maintenance: Triple therapy — Calcineurin inhibitor (tacrolimus > cyclosporine) + Antimetabolite (MMF > azathioprine) + Prednisone (tapered)
• Monitoring: Drug levels (tac trough), graft function (Cr, LFTs, echo, biopsy), infection prophylaxis (PJP, CMV, fungal), metabolic (glucose, lipids, bone)

Long-Term Complications

Complication	Prevention/Management
Acute rejection	Biopsy-proven; pulse steroids, T-cell depletion, antibody removal (AMR)
Chronic rejection (CAV, bronchiolitis obliterans, transplant glomerulopathy)	Optimize immunosuppression, control risk factors
Infection	Prophylaxis, vaccination (pre-transplant ideal), early diagnosis
Malignancy (skin, PTLD, Kaposi)	Sun protection, age-appropriate screening, mTOR inhibitors for high risk
Cardiovascular disease	Aggressive risk factor control (statin, BP, glucose, weight)
Renal dysfunction (non-renal transplants)	CNI minimization, avoid nephrotoxins

Patient Role in Success

• Strict medication adherence (missed doses → rejection)
• Infection precautions (hand hygiene, food safety, avoid sick contacts)
• Skin cancer surveillance (dermatology q6–12mo)
• Healthy lifestyle: Mediterranean diet, exercise, no tobacco, limit alcohol
• Regular follow-up: Labs q1–3mo, clinic visits per protocol

Transplantation trades one disease (organ failure) for a manageable chronic condition (immunosuppression). With adherence and modern regimens, 10-year graft survival exceeds 50–70% for most organs.